The 7 most recent market catalysts affecting $QGEN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 24, 2026
Corporate Catalyst
Neutral
Impact 65
Qiagen Launches QIAmini Benchtop System To Automate DNA And RNA Extraction For Smaller Research Labs
This headline represents a moderate corporate catalyst for Qiagen (QGEN) as it introduces a new product designed to capture a previously underserved market segment – smaller resear…
Sep 9, 2026
Corporate Catalyst
Bearish
Impact 55
UBS Maintains Neutral on Qiagen, Lowers Price Target to $47
UBS analyst Dan Leonard maintained a 'Neutral' rating on Qiagen but lowered the price target from $52 to $47. This action indicates that while the analyst doesn't see a strong reas…
Aug 24, 2026
Corporate Catalyst
Neutral
Impact 75
QIAGEN Appoints Jonathan M. Pratt CEO, Effective Sept. 1, Succeeding Thierry Bernard; Co. Reiterates Q3, FY26 Guidance
QIAGEN announced a significant leadership change with Jonathan M. Pratt taking over as CEO in September 2026. This is a notable corporate event, as a new CEO often brings strategic…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 55
Citigroup Maintains Neutral on Qiagen, Raises Price Target to $45
Citigroup analyst Brendan Digan has updated their outlook on Qiagen, raising the price target from $38 to $45 while keeping a 'Neutral' rating. This indicates that while the analys…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
JP Morgan Maintains Overweight on Qiagen, Raises Price Target to $50
JP Morgan analyst Casey Woodring has maintained an 'Overweight' rating on Qiagen (QGEN) and raised the price target from $45 to $50. This action signals increased confidence from a…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 92
Qiagen Q2 Adj. EPS $0.62 Beats $0.60 Estimate, Sales $535.000M Beat $527.484M Estimate
Qiagen announced its Q2 earnings, reporting adjusted EPS of $0.62, which surpassed the analyst consensus of $0.60, and sales of $535 million, exceeding the $527.484 million estimat…
Jul 15, 2026
Corporate Catalyst
Bullish
Impact 55
Qiagen Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak; Says Qiagen’s FDA-Cleared QIAstat-Dx Gastrointestinal Panel 2 Can Detect Cyclospora Infections In About An Hour As Part Of A 16-Target Gastrointestinal Pathogens Menu
Qiagen is leveraging a public health crisis, the growing Cyclospora outbreak in the U.S., to highlight its relevant diagnostic products. This is a positive development for Qiagen a…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.